Mono as Child or Teenager Tied to Risk of MS as Adult in Large Study There’s been a lot of buzz about this study, but I don’t think anyone should be surprised about its results. For years, researchers have suspected a link between the Epstein-Barr virus (EBV) — the…

People who contract infectious mononucleosis — colloquially known as “mono” — during childhood or adolescence are at a roughly two to three times greater risk of developing multiple sclerosis (MS) as adults, a large population-based study suggests. Notably, the study points to mono itself — independent of other factors…

Ublituximab, Potential Relapsing MS Therapy, Up for FDA Approval Like Ocrevus (ocrelizumab) and Kesimpta (ofatumumab), ublituximab targets the CD20 protein that’s found on the surface of B-cells in the immune system. It then binds to it and kills the cell, reducing the number of cells that are attacking the…

An investigational immunotherapy, ATA188 showed it could reverse disability and improve exercise capacity in people with progressive forms of multiple sclerosis (MS), Atara Biotherapeutics, its developer, reported in an update on a Phase 1 trial and its long-term extension study. EMBOLD trial findings based on MRI brain imaging…

Experiencing serious infections during adolescence is tied to an increased risk of developing multiple sclerosis (MS) later in life, but those occurring in childhood don’t increase MS risk, according to a new Swedish study. The study also found that certain types of infections, especially those that affect the central…

The HLA-DR15 haplotype — a set of gene variants that tend to be inherited together — in the HLA-DRB1 gene plays a role in autoimmune response and, in combination with environmental factors, contributes to the development of multiple sclerosis (MS), a study suggests. The study, “…

ATA188, Atara Biotherapeutics’ investigative T-cell immunotherapy, is safe, well tolerated, and able to ease disability and improve exercise capacity in patients with progressive forms of multiple sclerosis (MS), according to one-year data from a Phase 1 trial and its long-term extension study. Findings also showed that, after…

Genetic variants may contribute to increased levels of antibodies against proteins of the Epstein-Barr virus — a known environmental risk factor for multiple sclerosis (MS) — in MS patients and their siblings, a study suggests. The study, “EBNA-1 titer gradient in families with multiple sclerosis indicates a…

Cigarette smoking and an Epstein–Barr virus infection together represent a significant risk factor for multiple sclerosis (MS), suggesting that at least one path to this disease involves two factors working synergistically, a study reports. The study, “Smoking and Epstein–Barr virus infection in multiple sclerosis development,” was published…

Immune B-cells that proliferate unchecked when infected by the Epstein-Barr virus (EBV) appear to increase the risk of relapses in patients with multiple sclerosis (MS), a mouse study suggests. The study, “Epstein Barr virus‐immortalized B lymphocytes exacerbate experimental autoimmune encephalomyelitis in xenograft mice,” was published…

Atara Biotherapeutics‘ cell-based therapy ATA188 is safe and well-tolerated in people with progressive forms of multiple sclerosis (MS), and induces a sustained reduction in disability in a dose-dependent manner, findings from the first part of a Phase 1 clinical trial show. ATA188 had an…

Supporting evidence that infection with Epstein-Barr virus (EBV) could be one of the root causes of multiple sclerosis (MS), a recent study found all of its 901 early disease patients carry antibodies against this virus, meaning that all are or have been exposed to it. The study, “…

In response to the COVID-19 pandemic, Atara Biotherapeutics has temporarily paused patient enrollment in the second and randomized part of its ongoing Phase 1 clinical trial investigating ATA188 in people with progressive forms of multiple sclerosis (MS). People treated in the first, open-label part of this trial, however,…

Interaction between various Epstein-Barr virus traits and the composition of certain genes affects the risk of developing multiple sclerosis (MS), a study reports. The study, “The interaction of Multiple Sclerosis risk loci with Epstein-Barr virus phenotypes implicates the virus in pathogenesis,” was published in the journal…

Life is never how you expect or predict it to be. Things happen today that we couldn’t have anticipated. We have no easy or predefined path to fulfillment, joy, or nirvana. Forget about your navigation as your direction can — and will — change at any moment. My compass spun…

People with progressive forms of multiple sclerosis (MS) and past exposure to the Epstein-Barr virus are responding to a potential immunotherapy known as ATA188, tolerating the treatment well and with signs that suggest effectiveness, early updated data from an ongoing Phase 1 trial show. The research, “…

Infection with the human herpesvirus (HHV)-6A may increase the likelihood of having multiple sclerosis (MS), according to a new national study in Sweden. The research, “Serological response against HHV-6A is associated with increased risk for multiple sclerosis,” was presented by Anna Fogdell-Hahn, PhD, associate professor at the…

Multiple sclerosis (MS) experts discuss disease causes and current treatment options in a new video series released by the multimedia and peer-reviewed science journal, The American Journal of Managed Care (AJMC).  The free and online video series is part…

Early, positive safety results from a Phase 1 trial testing a potential immunotherapy, ATA188, in people with progressive multiple sclerosis will be detailed at the 5th Congress of the European Academy of Neurology (EAN) late next month, its developer, Atara Biotherapeutics, announced. ATA188 is an investigational and “off-the-shelf”…

Atara Biotherapeutics’ investigational ATA190, a cell therapy that wipes out immune B-cells infected with the Epstein-Barr virus (EBV), led to neurological improvements and reduced symptoms in patients with primary and secondary progressive multiple sclerosis (MS), a Phase 1 trial shows. The trial results were published in the Journal…

Analysis of post-mortem brain samples from multiple sclerosis (MS) patients and healthy individuals (without neurologic disease) showed that while signs of Epstein-Barr virus (EBV) infection are present in both groups of brains, EBV-positive immune cells were more prevalent and densely populated in the MS brain. The study reporting those findings,…

Infection with the common Epstein-Barr virus (EBV) may increase the risk of developing multiple sclerosis (MS), a new report from the  Cincinnati Children’s Hospital Medical Center says. Besides MS, the Epstein-Barr virus also raises the risk for six other disorders: systemic lupus erythematosus, rheumatoid arthritis, juvenile idiopathic arthritis, inflammatory…

United Arab Emirates scientists have found active Epstein-Barr virus in many multiple sclerosis patients’ brain cells, supporting the notion that it plays a role in the disease. The team found it in two types of brain cells — astrocytes and microglia. The virus can be active or lie dormant in…

Atara Biotherapeutics has received a green light to enroll U.S. patients into a Phase 1 trial of ATA188 for progressive or relapsing-remitting multiple sclerosis (MS). The study was initially launched in Australia, but with the U.S. Food and Drug Administration (FDA) having cleared the company’s application, the trial…

A strong immune reaction to an Epstein-Barr virus infection and low levels of vitamin D appear to increase the risk of multiple sclerosis (MS) independent of each other, said researchers in a presentation at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, France. Previous studies have shown that serum antibody titers…

Atara Biotherapeutics has started a Phase 1 clinical trial to assess ATA188’s safety and potential to treat progressive or relapsing-remitting multiple sclerosis. ATA188 is the company’s next-generation T-cell immunotherapy. It targets Epstein-Barr virus antigens that play an important role in the development of MS. An antigen is a molecule capable of…

Past infection with the Epstein-Barr virus (EBV) has been reported to increase the risk for multiple sclerosis (MS). Now, researchers have found a link between EBV and MS in three racial-ethnic groups, with African-Americans and Latinos showing a higher risk for MS than Caucasians.

Atara Biotherapeutics recently published an update of the company’s quarterly financial results and operational highlights, including the advancement of its T-cell based immunotherapy strategies for multiple sclerosis (MS) and cancer. One of the investigational therapies featured in the report is ATA188, a potential treatment for MS.

(Editor’s note: Tamara Sellman continues her occasional series on the MS alphabet with this second of two parts on terms starting with the letter “E.” Read the first part here.) When it comes to multiple sclerosis, mastering an understanding of the disease means you…

An investigational treatment called ATA188 that wipes out B-cells targeting the Epstein-Barr virus (EBV) has shown promise as a multiple sclerosis treatment, a Phase 1 clinical trial involving a small patient group indicates. The trial, conducted in Australia, covered six people with primary or secondary progressive MS. B-cells are a…